Groupe Bruxelles Lambert/€GBLB
1D1W1MYTD1Y5YMAX
Capital at risk
About Groupe Bruxelles Lambert
Groupe Bruxelles Lambert (GBL) is an investment holding company founded in 1902 and headquartered in Brussels, Belgium. The company operates primarily in the financial services sector, focusing on long-term investments in industrial, services, and financial companies across Europe. GBL aims to create long-term value by actively supporting the strategic and operational development of its investments, utilizing a diverse portfolio to ensure stable and sustainable returns.
- Ticker
- €GBLB
- Sector
- Finance
- Primary listing
- BSE
- Employees
- -
- Headquarters
- Brussels, Belgium
- Website
- www.gbl.be
GBLB Metrics
BasicAdvanced
€8.9B
-
-€4.96
0.67
€3.59
4.79%
Price and volume
Market cap
€8.9B
Beta
0.67
52-week high
€85.55
52-week low
€71.50
Average daily volume
87K
Dividend rate
€3.59
Financial strength
Current ratio
2.453
Quick ratio
1.86
Long term debt to equity
0.579
Total debt to equity
0.632
Interest coverage (TTM)
1.26%
Profitability
EBITDA (TTM)
917.9
Gross margin (TTM)
70.52%
Net profit margin (TTM)
-9.31%
Operating margin (TTM)
6.68%
Effective tax rate (TTM)
0.31%
Management effectiveness
Return on assets (TTM)
1.12%
Return on equity (TTM)
-3.83%
Valuation
Price to revenue (TTM)
1.406
Price to book
0.84
Price to tangible book (TTM)
2.22
Price to free cash flow (TTM)
-58.615
Free cash flow yield (TTM)
-1.71%
Free cash flow per share (TTM)
-1.277
Dividend yield (TTM)
4.79%
Forward dividend yield
4.79%
Growth
Revenue change (TTM)
9.29%
Earnings per share change (TTM)
530.23%
3-year revenue growth (CAGR)
0.45%
10-year revenue growth (CAGR)
5.45%
3-year earnings per share growth (CAGR)
55.64%
10-year earnings per share growth (CAGR)
2.84%
3-year dividend per share growth (CAGR)
23.06%
10-year dividend per share growth (CAGR)
6.01%
What the Analysts think about GBLB
Analyst ratings (Buy, Hold, Sell) for Groupe Bruxelles Lambert stock.
Analyst projections of the future price of Groupe Bruxelles Lambert stock.
Bulls say / Bears say
Private equity firm CVC and GBL launched a €10.7 bn cash bid to take Italy’s Recordati private, marking a major strategic push into the high-margin pharmaceutical sector (Reuters)
GBL completed a €0.5 bn acquisition of a 45% co-control stake in Rayner, bolstering its direct private asset portfolio in the high-growth ophthalmic MedTech sector (Reuters)
GBL finalised its €0.5 bn majority-stake purchase of BUKO Group on May 28, 2026, enhancing operational involvement and value creation in the temporary traffic management market (Reuters)
GBL fully exited its c.8% stake in Umicore in February 2026 by selling 19.6 m shares for €0.3 bn, eliminating future dividend income and upside from the recovering battery materials sector (Reuters)
The proposed €10.7 bn joint bid for Recordati is under European Commission review as Case M.12479, exposing GBL to lengthy antitrust approval processes and potential divestiture remedies (Eur-Lex)
On April 29, 2026, GBL sold 6 m Concentrix shares at $22.25 per share, reducing its stake below key governance thresholds and limiting its board influence over the CRM–BPO investment (Reuters)
Data summarised monthly by Lightyear AI. Last updated on 28 Aug 2026.
GBLB Financial Performance
Revenues and expenses
GBLB Earnings Performance
Company profitability
Upcoming events
No upcoming events
Funds containing GBLB
AllEURGBPUSD
Fund name | Fund size | €GBLB weighting |
|---|---|---|
iShares STOXX Europe 600 Financial Services€EXH2 | €102M | 1.01% |
iShares EURO STOXX Mid€DJMC | €572M | 0.73% |
iShares EURO STOXX Mid Cap£DJMC | £491M | 0.73% |
iShares STOXX Europe Mid 200€EXSD | €610M | 0.35% |
iShares MSCI Europe Financials Sector€ESIF | €1.7B | 0.17% |
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Market data provided by CBOE Europe and Deutsche Börse.